The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) confirmed on Wednesday 7 April that the cases of thrombosis, accompanied by a low level of blood platelets, are indeed side effects of the Covid-19 vaccine produced by the Anglo-Swedish firm AstraZeneca.
This conclusion—which does not call into question the benefit-risk ratio of the product—had not been completely excluded in the previous analysis conducted by the EMA (see EUROPE B12681A2).